Craig A. Erickson
YOU?
Author Swipe
Beyond the Fragile X protein: neighborhood characteristics explain individual differences in IQ and adaptive behaviors of Fragile X syndrome Open
Background Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability and is caused by reduced or absent Fragile X messenger ribonucleoprotein (FMRP). Cognitive and adaptive skills widely vary among individuals …
View article: FX ENTRAIN: scientific context, study design, and biomarker driven brain-computer interfaces in neurodevelopmental conditions
FX ENTRAIN: scientific context, study design, and biomarker driven brain-computer interfaces in neurodevelopmental conditions Open
Fragile X Syndrome (FXS), caused by the loss of function of the Fmr1 gene, is characterized by varying degrees of intellectual disability, autistic features, and sensory hypersensitivity. Despite phenotypic rescue in animal deletion models…
Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder Open
Adenylosuccinate lyase deficiency disorder (ADSLDD) is an ultra-rare autosomal recessive metabolic condition that leads to severe neurological impairment, with an estimated global prevalence of approximately 0.00125 cases per 100,000 indiv…
View article: Frontal cortex hyperactivation and gamma desynchrony in Fragile X syndrome: Correlates of auditory hypersensitivity
Frontal cortex hyperactivation and gamma desynchrony in Fragile X syndrome: Correlates of auditory hypersensitivity Open
Fragile X syndrome (FXS) is an X-linked disorder that often leads to intellectual disability, anxiety, and sensory hypersensitivity. While sound sensitivity (hyperacusis) is a distressing symptom in FXS, its neural basis is not well unders…
The Aberrant Behavior Checklist for Fragile X Syndrome: A Qualitative Clinician Evaluation of Content Validity Open
Objective: The current intense period of drug development for fragile X syndrome (FXS) and other neurodevelopmental disorders (NDDs) indications has highlighted the importance of behavioral outcome measures with strong psychometric propert…
View article: Auditory steady-state response deficits in Fragile X Syndrome implicate deficits in stimulus representation maintenance and GABAergic modulation
Auditory steady-state response deficits in Fragile X Syndrome implicate deficits in stimulus representation maintenance and GABAergic modulation Open
Background Fragile X Syndrome (FXS) is a rare, neurodevelopmental disorder caused by a mutation to the Fragile X messenger ribonucleoprotein 1 ( Fmr1 ) gene and characterized by sensory processing abnormalities and sensitivities, including…
View article: An iPSC model of fragile X syndrome reflects clinical phenotypes and reveals m<sup>6</sup>A- mediated epi-transcriptomic dysregulation underlying synaptic dysfunction
An iPSC model of fragile X syndrome reflects clinical phenotypes and reveals m<sup>6</sup>A- mediated epi-transcriptomic dysregulation underlying synaptic dysfunction Open
Fragile X syndrome (FXS), the leading genetic cause of intellectual disability, arises from FMR1 gene silencing and loss of the FMRP protein. N6-methyladenosine (m 6 A) is a prevalent mRNA modification essential for post-transcriptional re…
View article: Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership in Fragile X Syndrome
Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership in Fragile X Syndrome Open
Recent failures translating preclinical behavioral treatment effects to positive clinical trial results in humans with Fragile X Syndrome (FXS) support refocusing attention on biological pathways and associated measures, such as electroenc…
View article: Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD Open
This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a clinically and biologically defined subgroup of patients with Autism Spectrum Disorder (ASD), name…
View article: Frontal Cortex Hyperactivation and Gamma Desynchrony in Fragile X Syndrome: Correlates of Auditory Hypersensitivity
Frontal Cortex Hyperactivation and Gamma Desynchrony in Fragile X Syndrome: Correlates of Auditory Hypersensitivity Open
Fragile X syndrome (FXS) is an X-linked disorder that often leads to intellectual disability, anxiety, and sensory hypersensitivity. While sound sensitivity (hyperacusis) is a distressing symptom in FXS, its neural basis is not well unders…
View article: Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder
Accelerated Theta Burst Transcranial Magnetic Stimulation for Refractory Depression in Autism Spectrum Disorder Open
Purpose Major depressive disorder (MDD) disproportionately affects those living with autism spectrum disorder (ASD) and is associated with significant impairment and treatment recidivism. Methods We studied the use of accelerated theta bur…
View article: CNN Brain Label-Maker: Computer Vision Based ICA Rejection EEG based System Architecture
CNN Brain Label-Maker: Computer Vision Based ICA Rejection EEG based System Architecture Open
The electroencephalogram (EEG) is a practical and reasonably applied tool for researching brain disorders and behavior changes. EEG offers a minimally restricted and non-invasive method, where the significant difficulties in utilizing EEG …
View article: Safety, Tolerability and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist), in a Randomized Clinical Trial in a Subgroup of Patients with ASD
Safety, Tolerability and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist), in a Randomized Clinical Trial in a Subgroup of Patients with ASD Open
This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a specific subgroup of patients with Autism Spectrum Disorder (ASD), namely ASD Phenotype 1 (ASD-Phe…
View article: Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome
Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome Open
Recent failures translating preclinical behavioral treatment effects to positive clinical trial results in humans with Fragile X Syndrome (FXS) support refocusing attention on biological pathways and associated measures, such as electroenc…
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome Open
Background: Fragile X syndrome, with an approximate incidence rate of 1 in 4000 males to 1 in 8000 females, is the most prevalent genetic cause of heritable intellectual disability and the most common monogenic cause of autism spectrum dis…
Hypersensitivity to Distractors in Fragile X Syndrome from Loss of Modulation of Cortical VIP Interneurons Open
Attention deficit is one of the most prominent and disabling symptoms in Fragile X syndrome (FXS). Hypersensitivity to sensory stimuli contributes to attention difficulties by overwhelming and/or distracting affected individuals, which dis…
View article: RETRACTED: Safety and tolerability of STP1 (PDE 3,4 inhibitor and NKCC1 inhibitor), in a subgroup of ASD patients (ASD-Phen1)
RETRACTED: Safety and tolerability of STP1 (PDE 3,4 inhibitor and NKCC1 inhibitor), in a subgroup of ASD patients (ASD-Phen1) Open
The authors have requested that this preprint be removed from Research Square.
View article: Effects of AFQ056 on language learning in fragile X syndrome
Effects of AFQ056 on language learning in fragile X syndrome Open
BACKGROUNDFXLEARN, the first-ever large multisite trial of effects of disease-targeted pharmacotherapy on learning, was designed to explore a paradigm for measuring effects of mechanism-targeted treatment in fragile X syndrome (FXS). In FX…
Genetic syndromes are prevalent in patients with comorbid neurodevelopmental disorders and catatonia Open
Catatonia occurs at high rates in idiopathic and syndromic neurodevelopmental disorders. At our institution's multidisciplinary catatonia clinic, clinical genetic testing (including microarray, fragile X PCR and methylation, autism/ID expa…
View article: Gamma spectral event power is elevated in Fragile X Syndrome and associated with single trial gamma power during auditory chirp
Gamma spectral event power is elevated in Fragile X Syndrome and associated with single trial gamma power during auditory chirp Open
Background Fragile X syndrome (FXS) is a neurodevelopmental disorder resulting from silencing of the FMR1 gene. One of the most common and debilitating symptoms of FXS is sensory hyperarousal, especially in the auditory domain. Although th…
View article: Empirical Frequency Bound Derivation Reveals Prominent Mid-Frontal Alpha Associated with Neurosensory Dysfunction in Fragile X Syndrome
Empirical Frequency Bound Derivation Reveals Prominent Mid-Frontal Alpha Associated with Neurosensory Dysfunction in Fragile X Syndrome Open
The FMR1 gene is inactive in Fragile X syndrome (FXS), resulting in low levels of FMRP and consequent neurochemical, synaptic, and local circuit neurophysiological alterations in the fmr1 KO mouse. In FXS patients, electrophysiological stu…